Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma

Objective: Gemcitabine plus nab-paclitaxel (GnP) is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC). S-1, an oral fluoropyrimidine derivative, as compared with gemcitabine, is non-inferior in terms of overall survival (OS) and is associated with lower hematologic...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Zhou Zhu, Hui Tang, Jinrong Ying, Yuejuan Cheng, Xiang Wang, Yingyi Wang, Chunmei Bai
Format: Artykuł
Język:English
Wydane: China Anti-Cancer Association 2023-10-01
Seria:Cancer Biology & Medicine
Hasła przedmiotowe:
Dostęp online:https://www.cancerbiomed.org/content/20/10/765